The A.D.A.M. offering is now closed and is no longer accepting investments.

A.D.A.M.

An on-demand personalized implant manufacturing infrastructure

A.D.A.M.

An on-demand personalized implant manufacturing infrastructure

Stamford, CT
Biotechnology
A.D.A.M. develops an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.

$134,063

raised
163
Investors
$30.8M
Valuation
$2.93
Price per Share
$293.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left

$134,063

raised
163
Investors
$30.8M
Valuation
$2.93
Price per Share
$293.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left
This offering ended on May 01, 2022 and is no longer accepting investments.

Reasons to Invest

Disrupt a growing market: The orthopedic implants market is expected to reach $79.5 billion in 2030.
Support innovation: A.D.A.M. leading the way in orthopaedics implant production with 3D printing methods.
Improve production times: Competitors in the implant industry have an average 2-4 weeks delivery time, while we are aiming to offer 1-3 day delivery.

OVERVIEW


Implant manufacturing, one 3D print at a time

A.D.A.M. (Advanced Development of Additive Manufacturing) is a developer of an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.  


Currently in the Research and Development stage, A.D.A.M. is designing for medical professionals to complete all steps of the implant printing process from 3D-modeling to receiving a sterilized personalized device, ready for implantation. As a pre-revenue company, A.D.A.M. has identified potential growth opportunities in the orthopaedic surgery, oncology, and CMF, neuro-, and plastic surgery markets.


The company has developed MVP for its printer, materials, digital platform, and has a Quality Management System in place. The company is about to start the animal trials as per the FDA requirements.



THE PROBLEM


Implants are costly and invasive

Many professionals are rethinking global healthcare models due to COVID-19. The basic demand for materials (such as human tissue and organs) remains largely unmet due to supply chain vulnerabilities. The orthopaedic market is currently dominated by titanium implants, which are costlyhave long delivery times, are rarely personalized to the needs of the patients, and typically require a second surgery to extract internal metal fixation.


*Images are computer generated demo versions. Product is still currently under development.

THE SOLUTION


Bone implants made from 3D printing methods

A.D.A.M.’s platform consists of bone implants, printers, materials, digital platform, and our Quality Management System. We create 3D bone implants from ceramic bio-glass for flat bone implants using a Binder Jetting Printing (BJP) method. For tubular bone implants, we use modified biopolymer with a Fused Filament Fabrication (FFF) printing method. The overall production time for us to develop a 3D implant will take up to 24 hours.


*Image is computer generated demo versions. 


Our process


1. Implant modeling: Patients or healthcare providers upload and securely store MRI and CAT scans on our digital platform.  



2. Implant production: Certified clinicians use the platform to create a 3D model of the implant based on the patient's medical data.



3. Implantation: Medical professionals receive a sterilized 3D printed bone implant ready for use and a set of Quality Management System procedures.



4. Recovery: There is no need for reoperation to extract implant elements. Our bone implants are biodegradable, stimulate osteogenesis, and are fully replaced by the bone tissue over time.


THE MARKET


Disrupting a market over $47 billion

Our target markets are orthopaedic surgery, oncology, and CMF, neuro-, and plastic surgery. The orthopaedic implants market is estimated at $47 billion for 2019, and expected to reach $79.5 billion in 2030 due to an aging population and an augmented incidence of orthopaedic diseases.



Based on our internal research, competitors in the implant industry have long delivery times of at least 2 to 4 weeks on average, whereas we plan to offer 1-3 day delivery. We are able to keep production costs low because of our material composites and 3D printing methods.



Most competitors offer implants made of either biopolymer or bioceramic implants, while we offer both. The market leader OPM does not offer biodegradable materials at all.


OUR TRACTION


FDA clearance by 2022

In August 2020, FDA confirmed 510(k) eligibility for A.D.A.M. biopolymer and bioceramic bone implants. We have 4 provisional patents (2 for materials and 2 for printers) in the U.S., along with 2 patents for materials in Ukraine.


A.D.A.M. plans to complete the animal studies required by the FDA in 2022. No human trials are required. FDA clearance is expected in late 2022 - early 2023.



OUR ADVISORY BOARD



A.D.A.M prides ourselves on the established team of advisors we have put together. Our Advisory Board consists of top minds in orthopaedics, material science and 3D printing, chemistry, innovations development, business and digital strategy. 


With calibre of people such as former DARPA director, a top strategy advisor for Secretary of Defense and NATO, to name a few, we are collectively ready to disrupt the health care and 3D printing industry on a scale.




WHY INVEST


A path to growth

A.D.A.M.’s product has unique characteristics that we believe no other company in the industry has. Bone implants are just the beginning - in the years to come A.D.A.M. aims to launch R&D of blood vessel implants, heart valves, and bronchial implants.

*Image is computer generated demo versions. 




Insert Video

In the Press

Entering Altered Carbon: A.D.A.M. – Developers of Personalized Implant Printing

Science fiction and Hollywood TV series are becoming a reality thanks to Ukrainian technology startups such as A.D.A.M., which helps customers print new organs, bones, or tissue on a 3D printer.

A First Look at 3D Printed Bioresorbable Bone Implants From A.D.A.M.

A.D.A.M. is on the cusp of releasing 3D printed bioresorbable bone implants. The implants would, if successful, be completely absorbed by the body. Recovery times would improve; patients would undergo fewer surgeries; the implant is personalized to each patient.

FDA Confirms 510(K) Eligibility for Biotech Company A.D.A.M. – 3D Printed Bones Are to Become a Reality in Less Than 2 Years

In recent months, Global healthcare system problems have become strikingly evident. The outbreak of COVID-19 has exacerbated existing issues in the industry, causing many professionals to rethink the healthcare models currently in place.

Farmington startup developing 3D-printed bone implants

If all goes according to plan, healthcare facilities in the next few years could begin purchasing 3D-printed bone implants that are being developed by a Farmington-based startup called A.D.A.M.

And the Winners of Startup Grind’s First Ever Global Pitch Battle Are…

Startup Grind hosted its first-ever virtual Global Pitch Battle Competition in late September 2020 where startups from all around the world battled it out to win amazing prizes, global recognition, and of course, bragging rights.

The Economist

What next? 22 emerging technologies to watch in 2022

Offering Summary


Company

:

Advanced Development of Additive Manufacturing, Inc.

Corporate Address

:

9 W Broad St, Suite 320H, Stamford, CT 06902

Offering Minimum

:

$9,997.16

Offering Maximum

:

$1,069,994.98

Minimum Investment Amount

(per investor)

:

$293.00











Terms


Offering Type

:

Equity

Security Name

:

Series A Preferred Stock

Minimum Number of Shares Offered

:

3,412

Maximum Number of Shares Offered

:

365,186

Price per Share

:

$2.93

Pre-Money Valuation

:

$30,788,952.80











Please refer to the Company Securities section of the Offering Memorandum for further details regarding the Series A Preffered Stock rights for the securities sold in this offering.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within the first 72 hours and receive additional 15% bonus shares.

 

Super Early Bird Bonus

Invest within the next 72 hours and receive additional 10% bonus shares.

 

Early Bird Bonus

Invest within the next 7 days and receive an additional 5% bonus shares.

Amount-Based:

$500+

Perk: 2% Bonus Shares

$1000+

Perk: 3% Bonus Shares

$2,500+

Perk: 5% Bonus Shares

$5,000+

Perk: 10% Bonus Shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Advanced Development of Additive Manufacturing, Inc.'s will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Preferred Stock at $2.93 / share, you will receive 110 Series A Preferred Stock, meaning you'll own 110 shares for $293. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Inter company debt or back payments. Vendor payments. Salary payments made to one’s self, a friend or relative.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$77,745.00 USD
$1,364.00 USD
Cash And Cash Equivalents
$4,069.00 USD
$1,364.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$128,661.00 USD
$120.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$92,736.00 USD
-$90.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Last Chance: The A.D.A.M. Investment Opportunity Closes Tomorrow - Don’t Miss Out!

about 2 months ago

There are only 24 hours left to join the biotech startup named by The Economist as one of the "Emerging Technologies to Watch in 2022.”

According to the FDA, the Covid-19 pandemic has only emphasized the need for 3D printing in healthcare. A.D.A.M. has developed a robust implant-care system that is set to revolutionize the market with 3D printed biotech, offering a new era in orthopaedic healthcare. 

With the orthopaedic implants market expected to reach $79.5 billion in 2030, don’t miss this opportunity to invest in and own part of A.D.A.M. now. 


A.D.A.M. has been marking numerous milestones and highlights, including;

  • We recently announced our partnership with the Mount Sinai Innovation Partners incubator program, providing a clear path for commercialization of our technology in the US

  • We passed pre-clinical trials in accordance with ISO standards, with results submitted to the FDA 

  • This resulted in the FDA confirming in August 2020 the 510(k) eligibility for A.D.A.M. biopolymer and bioceramic bone implants

  • A.D.A.M. has developed proprietary printing materials, holding several patents for materials and printers, including two published PCT patents for materials (US), and two provisional patents for printers (US)

  • We have passed several mechanical tests with Yale Medicine and the University of Connecticut

  • We’ve been featured in numerous publications, articles, broadcast features, interviews, panels, and innovation shortlists 


With the orthopaedics market predicted to grow exponentially, now is the time to join one of the premiere biotech companies in this space.


Haven't invested yet? This is your last chance before the StartEngine campaign closes tomorrow. Join us now as we are poised for continued growth and success!


Ending Soon: Don’t Miss Your Chance To Invest In A Venture Heralding The Future Of Regenerative Medicine

about 2 months ago

We are very excited to announce that within the span of just a few months, A.D.A.M. has gained over 150 investors. 

Our crowdfunding campaign is ending in just three days, so act now to invest and own a part of one of the “emerging technologies to watch in 2022” (The Economist). 



Need a refresher about what we’re building?

Founded in 2018, A.D.A.M. (Advanced Development of Additive Manufacturing) has created proprietary 3D printing technology and material composites to print personalized bone implants. Our approach to implant manufacturing – using 3D printing – offers a cost-effective production process whilst maintaining implant integrity and quality. 

An alternative to the titanium counterparts prevailing in the market today (e.g. titanium hip implants), A.D.A.M.'s biodegradable and bioresorbable implants are not only easier and more affordable to produce, they also support the progressive development of tissue engineering for improved surgical results. 

Made with material composites including modified bio-polymers, the implants stimulate osteogenesis, meaning they are fully replaced by the bone tissue over time. Therefore, there is no need for reoperation to extract metal fixation elements (comparatively, titanium implants need to be surgically replaced every ten to twenty years).



"With A.D.A.M.’s innovative approach, bones are just the beginning," shares CEO Denys Gurak. "A.D.A.M. has plans to expand into production of other tissues, and thus establish a movement to overcome body limits and open new horizons for healthcare”. 

"The standardization of technology and the practical implementation of artificial tissue production will open the way to the future of regenerative medicine as an industry.” 

With our equity crowdfunding campaign ending this Saturday 30th April, join now to be a part of the future of medicine. 


All photos taken in the A.D.A.M. Research & Development lab 

How Medical Implant Cost Effects Medicine and Treatments

2 months ago

As medical implant technology has continued to grow and Orthopedics has become more specialized, the cost of medical implants has also increased. This is particularly apparent in the Orthopedic implant market. Expenses for Orthopedic implants have risen faster than almost any other type of implant. While this price rise may initially seem concerning, it is essential to understand why these costs are increasing and how they affect both patients and the medical industry. In this blog post, we will explore the reasons for rising implant prices and examine how they impact both patients and doctors.



Orthopedic implants are growing more expensive, but they are also becoming more specialized. In the past, Orthopedic implants were primarily used to replace joints or bones damaged by trauma. However, Orthopedics has since become a highly specialized field, and Orthopedic implants are now used to treat various conditions, from congenital deformities to degenerative diseases. As Orthopedics has become more specialized, the cost of Orthopedic implants has increased.

One reason for the increasing cost of Orthopedic implants is the development of new technology. To treat more complex conditions, Orthopedic surgeons require ever-more sophisticated implants. The development of new Orthopedic technologies is a costly process, and these costs are passed on to patients in the form of higher prices. In addition, Orthopedic implants are often made from expensive materials, such as titanium or stainless steel. These materials must be carefully machined to meet the precise specifications required for Orthopedic surgery.

The Big Struggle In The Implant Industry

The health care system spends a lot of money on implants, but the prices are still too high. There's no way for hospitals or other suppliers to track their inventory correctly, so they often lose products and have patients pay more than necessary because those losses add up fast. Implementing effective supply management practices such as proper tracking techniques can solve this problem without requiring costly last-minute transportation solutions, which everyone involved - manufacturers/suppliers and healthcare providers- would benefit from.

The current struggles faced by hospitals when trying to control costs associated with surgery only makes these problems worse: there have been numerous instances where usable implant inventories were poorly tracked, resulting in higher rates of surgical site infections, unplanned readmissions, and other postoperative complications. To solve this problem, Orthopedic surgeons require ever-more sophisticated implants. The development of new Orthopedic technologies is a costly process, and these costs are passed on to patients in the form of higher prices.




A.D.A.M Changes The Playing Field in Implant Technology

A.D.A.M. (Advanced Development of Additive Manufacturing) is an innovative 3D implant manufacturing biotech recently named one of the "emerging technologies to watch in 2022" by the Economist. A.D.A.M's technology will allow for the customization of implants, which is a huge shift in the Orthopedic industry as it has long relied on "one size fits all" solutions.


The ability to produce implants specific to each patient will have several benefits. First, it will allow Orthopedic surgeons to treat patients with conditions previously considered untreatable. Second, it will reduce the risk of complications associated with Orthopedic surgery. Third, it will lower the cost of Orthopedic implants. A.D.A.M's technology is still in its early stages, but it has the potential to revolutionize Orthopedics and make Orthopedic surgery more accessible and less expensive for everyone.


Denys Gurak founded A.D.A.M. as an innovative solution to traditional titanium bone implants that are costlier, time-consuming, and invasive. The 3D-printed bone implants by A.D.A.M are made using biopolymer, making them highly personalized for patients and eliminating the need to have revision surgery for extraction, resulting in reduced cost and hospital stay.

 

CEO Denys Gurak Announces Acceptance into Mount Sinai Innovation Partners Incubation Program

2 months ago


Dear investors and followers, 


Today I have a bittersweet update. 

In exceptional news, A.D.A.M. has an exciting development to share  -  we were accepted to the Mount Sinai Innovation Partners incubator program, Elementa Labs in New York City, USA.

Why is this bittersweet? Because this means that we are less reliant on our fundraising efforts through StartEngine.  So, if you have been considering investing in A.D.A.M. and our technology, now is the time to do so. 

Mount Sinai Innovation Partners program means we will be exploring ways to advance and commercialize our core technology platform with the Mount Sinai, a top-rated health system in the US and worldwide. 

Mount Sinai leadership team was particularly supportive when the war in Ukraine started, offering the R&D Department to relocate to NYC from Odesa, Ukraine, and we are considering this one of the options. 

Our StartEngine campaign will be closing on April 30th, so you only have two weeks to join as an investor. 

To invest now, or find out more, simply check out our StartEngine page. I look forward to welcoming you on board. 


Best, 

Denys Gurak

Orthopedics Equipment: What You Need to Know About Common Procedures

2 months ago

Orthopedics Equipment: What You Need to Know About Common Procedures

Orthopedics is a branch of medicine that deals with the diagnosis and treatment of injuries and disorders of the musculoskeletal system. This includes everything from fractures and dislocations to arthritis and sports injuries. In order to properly treat orthopedic conditions, doctors rely on specialized equipment. In this blog post, we will look at some of the most common orthopedic procedures and the equipment used to perform them.


A.D.A.M will provide an on-demand, personalized implant manufacturing infrastructure with related services that can be provided remotely or at a facility via a full scope of capabilities designed to make this process more efficient for both patients and providers alike.



3D Printing in Orthopedic Surgery

The use of 3D printing in Orthopedic surgery has been a major development that allows for an easier and quicker treatment time when compared with traditional methods. The first approval from FDA came about because this technology allowed doctors to replace metal crowns, which were previously used on teeth as replacements due largely to their durability but also sometimes resulted in too much wear over the years down the line before replacement is needed again--a process taking hours or days depending on how complex your condition may be.


This technology has also been used in the orthopedic field to create trabecular metal (TBM) scaffolds used as an alternative to autologous bone grafts. TBM scaffolds are still relatively new, but they have shown great promise in helping patients heal from orthopedic injuries and disorders.


Some of the most Common Procedures

The list of orthopedic surgeries is extensive, and each one addresses a different part or aspect in the body. While they're still invasive procedures with the potential for complications, many people consider these normal activities given how routine it has become over time.


Some of the most common procedures include:

  • Knee Replacement Surgery
  • ACL Surgery
  • Hip Replacement Surgery
  • Shoulder Replacement Surgery
  • Joint Fusions
  • Shoulder Arthroscopy
  • Knee Arthroscopy


Many of the surgeries mentioned have some form of titanium implant used in them. As discussed in a previous post, there are many problems with titanium. The majority of titanium orthopedic implants today are costly, rarely customized, and require a second surgery to remove metal fixations.


The next generation of orthopedic implants will be made with biocompatible materials that are patient-specific and can be printed on demand. This will allow for better outcomes, shorter surgery times, and reduced implant costs.


A.D.A.M is Moving Ortho Implants into the Future

3D printing is an incredible technology that has revolutionized our lives, work, and play. It's also improved implants for those who need prosthetics or orthopedic implants. A.D.A.M focuses on providing doctors with high-quality medical-grade plastic materials so their patients can get back up again quickly after surgery without having any negative effect long term health-wise due to its biodegradable properties, unlike other alternatives out there, such as polysulfone, which causes inflammation and at worst leaves you needing another operation because it isn't functioning the way it should.



The company started with the idea that any part of your body could be replaced, much like how cars are serviced. The team worked on bone implants and developed proprietary 3D printing technology; they also used materials composites to craft an implantable ceramic shell around it, so you don't need metal plates or other hardware.


This innovation in orthopedic implants is just one way that A.D.A.M is moving ortho implants into the future. To learn more about our company and what we do, visit our website or contact us today. We would be happy to answer any questions you may have.





New Closing Date

2 months ago

Thank you for your investment and for joining us on our journey. Our campaign will be ending early with a new closing date of 4/30/22. We will continue to accept commitments until then and investors who have made commitments will have up to 48 hours before the new deadline to cancel their commitments.

CEO speaks at a 3D printing conference

2 months ago

Curious to learn about the business model behind point of care 3D printing?

Our CEO Denys Gurak was recently a guest speaker at the 2022 3D Bioprinting Conference, hosted in the Netherlands and online https://www.3dbioprintingconference.com/


Denys spoke in depth about the new business models in healthcare; you can watch Denys' presentation here https://youtu.be/8XFPBnbSq8o


The State of Medical Device Manufacturing: How Companies are Succeeding

3 months ago

Medical device manufacturing is a booming industry. Companies invest billions of dollars in research and development to create cutting-edge medical devices with multiple applications. Orthopedics, implants, bone graft substitutes, tissue engineering, and regenerative medicine are just some segments that are seeing significant growth. This article will look at some of the strategies that companies are using to succeed in this competitive market.


Some of the Different Strategies

One strategy that companies are using is securing FDA approvals. This gives them a competitive edge, as it assures customers that the products are safe and effective. Another strategy is acquisitions/partnership agreements. These can take many different forms, such as joint ventures, collaborations, or expansions into new markets. By doing this, companies can expand globally while also securing intellectual property rights that will protect their investments long term.


Finally, companies invest in research and development to create new and innovative products. This is essential for staying ahead of the competition and keeping up with the latest trends in the industry. Implants and bone graft substitutes have seen a boom in recent years as there's been a heavy focus on new materials. One reason for this is that orthopedic devices are becoming increasingly sophisticated. They can now perform multiple functions, such as restoring joint function and repairing bone defects.


The Growing Use of Biocomposite Materials in Medical Devices

One of the materials that are seeing a lot of growth in the medical device industry is biocomposite materials. These are made from natural fibers and resins, which gives them many advantages over traditional plastics. They are biocompatible, meaning that they are safe for use in the body. They are also environmentally friendly, as they can be recycled and are not harmful to the environment.


Finally, they have excellent mechanical properties. This makes them ideal for use in medical devices, as they can withstand the stresses and strains that are placed on them. Biocomposite materials are already being used in several medical devices, including orthopedic implants and bone graft substitutes. As the industry grows, we can expect to see them being used in even more devices.


Biocomposite materials could be a combination of biphasic calcium phosphate and PLDLA, for one example. Biomaterials are materials that have been designed to substitute for human tissue and provide a function where it is not normally found in the body or has been damaged. Orthopedic biomaterials can be used as components of devices used in joint replacement surgeries, bone repair systems or even guided surgical procedures when necessary.


A.D.A.M, The Next Generation in Medical Devices

The A.D.A.M team has been at the forefront of new technology in bringing patients back into their full range of motion with 3D printing and material composites, which allows them to produce customized implants without sacrificing quality or cost-effectiveness. The orthopedic devices market is growing and changing rapidly, with an increasing demand for implants that can be customized to individual patients.


A.D.A.M has responded to this demand by developing a new generation of medical devices made from advanced composites using additive manufacturing technology (AM). This allows them to produce customized implants without sacrificing quality or cost-effectiveness. They can also produce them much more quickly, which is essential in a constantly changing market.


The A.D.A.M bone implants are a safe and natural way to stimulate osteogenesis. Over time, these bio-based products will be fully replaced by your tissue, meaning there's no need for additional procedures, extraction, or replacement of individual pieces (which could cause pain).

A.D.A.M. Video Update on Operations During Russia’s War on Ukraine

3 months ago


Orthopedic Implants: A Quick Overview of Their Uses

3 months ago

Orthopedic implants are devices that are used to replace or support injured or diseased bone. Orthopedic implants can be made from a variety of materials, including metals, plastics, and ceramics. They are used to treat a wide variety of conditions, including fractures, arthritis, and spinal deformities. In this blog post, we will give a brief overview of the different types of orthopedic implants and their uses.


There are three main types of orthopedic implants:


- Joint replacements. Joint replacements are used to replace a damaged joint, such as a hip or knee joint.


- Spinal implants. Spinal implants are used to support the spine and treat conditions such as spinal deformities and fractures.


- Orthopedic trauma devices. Orthopedic trauma devices are used to treat fractures and other injuries.


Other orthopedic implants include devices for tissue fixation to bone such as suture anchors and screws for ligament reattachment and are made from a variety of materials, including metals, plastics, ceramics, and more recently biological materials that can assist in bone growth. The type of material used depends on the specific injury or condition being treated. For example, metal implants are often used for joint replacements because they are strong and durable. However, plastic or ceramic implants may be used for some spinal conditions because they provide better stability and support.


Orthopedic implants can be placed surgically or nonsurgically. Surgical placement is usually necessary for joint replacements, sports-related injuries, trauma injuries, and some spinal conditions. Orthopedic implants can be permanent or removable depending on many factors. Orthopedic implants are an important part of treating many injuries and conditions. They can help improve function and quality of life.


New Materials and Advancements

Orthopedic implants are made from highly developed materials that require extensive testing before they can be used in an orthokinetic implant. The most common types have had great success in clinical trials and proven successful outcomes. Orthopedic implants are also available in different sizes, shapes, and colors to better match the surrounding tissue. In some cases, the implant may be made from a patient's own cells or tissues to reduce the risk of rejection.


Advancements in surgical techniques have also helped improve outcomes for patients who receive orthopedic implants. For example, minimally invasive surgery can help reduce recovery time and scarring. Orthopedic surgeons are constantly working to develop new materials and surgical techniques to improve the safety and effectiveness of orthopedic implants. Orthopedic implants are an important part of treating many injuries and conditions. They can help improve function and quality of life. New materials and advancements continue to make orthopedic implants more effective.


A.D.A.M Ushers in A New Era

A.D.A.M, which uses proprietary 3D printing technology and material composites to manufacture implants, is at the forefront of new technology in the mission to restore the range of motion for patients seeking treatment.  A.D.A.M. 's exclusive approach to implant manufacturing – using 3D printing – lets enhanced production of personalized implants that are cost-effective and quickly delivered without compromising on the quality.


Amid the COVID-19 pandemic and the need to restructure processes, basic needs for materials (such as human tissue, organs, and titanium implants that dominate the market) are not being met. A.D.A.M. 3D-printed implants are not only more convenient to produce locally, but they also facilitate progress in tissue engineering, so multiple surgeries and implant replacements are not needed.


Its product is unique to the industry and is unlike anything else currently offered, especially at its on-site level. With a burgeoning pipeline, A.D.A.M is looking at additional medical devices such as blood vessel implants, heart valves, and bronchial implants.

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, A.D.A.M. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in A.D.A.M. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Press Update! A.D.A.M. featured on global innovation news platform Springwise

3 months ago

We were pleased to be approached by innovation intelligence platform Springwise to be the subject of a feature article. A global innovation news source, Springwise was established in 2002, and selectively features companies that exhibit ‘innovation that matters’. 


"Springwise is the global innovation intelligence platform for positive and sustainable change, providing foresight into the most innovative thinking and ideas on the planet. We are the place of record for innovation that matters."


Click here to read in full.


Notice of Funds Disbursement

4 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, A.D.A.M. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in A.D.A.M. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Sharing Progress: Highlights of 2021 for A.D.A.M. (Part 1)

4 months ago

We have a number of exciting pending announcements coming in the next month, and are looking forward to sharing some pivotal news about our progress. Whilst the final details are being confirmed, we’re proud to share a snapshot of achievements from the last year, particularly as many relate to the upcoming announcements. Sharing progress and transparency is important to us, and we invite you to submit any queries you may have regarding our work. 


2021 was a huge year for A.D.A.M., making significant progress with our technology, expanding our number of partnerships, and increasing our market and public awareness. We’ve additionally been involved in numerous events, seminars and conferences, filed patents, and made new hires. And of course, all whilst navigating the pandemic, supply chain challenges, and working as a team across multiple continents. 


In 2021 we embraced some internal changes. Firstly, we rebranded from A.D.A.M. Project to A.D.A.M. Bioprinting, including updates to the website. The US team also moved offices from the University of Connecticut Farmington site to the Stamford site. Following that, we launched the formal procedure for Advisory Board meetings, and elected a Chairperson of the Advisory Board; Dr. Phillip Karber


FDA Clearance Testing

In August 2020, the FDA confirmed 510(k) eligibility for A.D.A.M. biopolymer and bioceramic bone implants. This means human trials are not required, however animal studies are required for final FDA clearance. 2021 saw us finalize the protocol of the pilot study on rabbits with Charles River Laboratories, followed by samples being delivered for study. 


Patents

In August we filed two PCT patent applications for materials, and in November filed a PCT (Patent Cooperation Treaty) patent for our binder jet printer (BJP). This now means we have four provisional patents in the U.S. (two for materials and two for printers), and two patents for materials in Ukraine.


Research & Development

Our proprietary technology leapt forward in development throughout 2021. A main focus of the R&D team in Odesa has been our FDM printer, which utilizes the fused filament fabrication method to produce 3D implants. 


Completed work on the printer and associated sterilization system includes;

  • Designing and building extensions and new features of the printer and sterilization system, including a stand for controlling scrubbers, a revised printer control system, the feeding system, mounting brackets, extruders, pumps, lighting, the holding cabinet, air compressor models, the evaporator module, and the interface

  • Testing sterilization algorithms and various configurations to prepare for printing with the medical filament

  • Operational tests, including of the POP, relay, evaporator, and automation algorithm


Therefore we’re happy to announce we passed a number of structural milestones, and subsequently have been working on the second iteration of the FDM printer. 


Additionally, work continued on the ceramic printer. Highlights included;

  • Testing and amending printing settings to change the properties of the implants

  • Producing ceramic implants with adjusted sintering modes

  • Completing test prints with the hydroxyapatite-bioglass composition based on a cylindrical sample


Printed Bone Implant Samples

2021 saw many iterations of bone samples printed, many ending up in overseas destinations for testing. Implant samples produced included;

  • Polymer and ceramic implant samples which were sent to Board Member Dr. Horowitz for testing at Yale

  • Ceramic jaw parts and tibia fragments for medical analysis

  • A ceramic sample of the humerus bone head was printed and sent to Cincinnati for the Cool Parts Showcase competition

  • A series of samples for Charles River and Levin Center. These samples utilized new settings for the firing process, and a modified formula of the baked powder tested for changing its properties during baking.

  • ‘Dog Bone’ samples for biomechanical testing at UConn 

 

During the latter part of the year the R&D team worked on preparations to utilize a new, validated production space at a pharmaceutical plant specifically for the production of samples for the FDA animal trials. These trials are just one of the announcements soon to be made! Stay tuned for Part 2..


As A.D.A.M. continues to deliver positive results and measurable progress, we encourage you to join us as an investor, and be part of the future of healthcare. 









Pictured: Head of R&D Arkadii Bohdan MD in the lab, and with printed samples

A.D.A.M. Submits Response to FDA For Policy Consideration

5 months ago

Recently the FDA called for input from the medical device industry, manufacturers, health care providers and other stakeholders regarding 3D Printing Medical Devices at the Point of Care. 


The purpose of this input  is to inform future policy development and regulatory approaches by the FDA. Given 3D printing at POC is a core pillar of our business, we have submitted a detailed response in order to help steer future policy. Our submission includes detailed information from our in-house R&D team (comprising doctors, surgeons, engineers, and 3D printing specialists) to assist the FDA.   


We have been working on a 3D printing at point-of-care (POC) model since 2018, and are one of the early adopters of this model. Over the last two years the Covid-19 pandemic has accelerated the adoption of 3D printing in healthcare in order to mitigate supply chain disruptions. CEO Denys Gurak was last year invited to speak at a healthcare forum Breakthrough Medical Applications of Additive Manufacturing, and included details of POC manufacturing in the presentation. The forum was hosted by the Additive Manufacturing Coalition; an NGO working to educate the US government on the benefits AM brings to the economy and healthcare sector. 


At A.D.A.M., we have been working diligently to FDA requirements, and in August 2020 we received FDA confirmation of 510(k) eligibility for our biopolymer and bioceramic bone implants. This eligibility is a regulatory pathway to market clearance, meaning no human trials are required. 


We’re pleased to share this submission with you, and encourage any questions you may have about the content. 


Breaking News: A.D.A.M. Announces New Appointments

5 months ago

We are excited to announce several new appointments here at A.D.A.M. As we continue working towards commercialization, we are delighted to be engaging several highly experienced professionals to join us at this time. 


Firstly, we're honored to announce the appointment of Colonel Carl Savory MD as A.D.A.M.'s new Chief Medical Officer.  Engaging Dr. Savory as CMO is a key milestone for the company, as he is a well-respected expert in orthopaedic surgery, and brings a wealth of experience with him. A Special Operations Surgeon and orthopaedic specialist, Dr. Savory served a long and decorated career in the military, before retiring in 1987 and working in private practice at the Hughston Clinic in Columbus, Georgia. 

Dr. Savory graduated Medical School at Arizona University, and completed his surgical internship and orthopaedic residency at Letterman Army Medical Center and Shriners Hospital for Crippled Children in San Francisco. He served as Chief of Orthopaedics at Womack Army Hospital in Fort Bragg, NC, went on to be appointed as the first Delta Force surgeon, and later the first Command Surgeon of the Joint Special Operations Command (JSOC). In 1983 Dr. Savory attended John Hopkins and completed a Fellowship in Adult Reconstructive Surgery, following which he served at Walter Reed as Assistant Chief of Orthopaedics.

After a period in private practice, Dr. Savory was recalled to active duty in 1990 for the first Gulf War, serving in the 274th Forward Airborne Surgical Team. Following this time, he returned to practice at the Hughston Clinic, and retired in 2016. Since retiring from active practice Dr. Savory has served as a consultant to his former Clinic and the Jack Hughston Memorial Hospital. He is also the Vice Chairman of National Infantry Museum, and is the Advisory Board member for Mercer Medicine Harris County.


We also have two professionals with extensive political and international experience joining the Advisory Board;

Christopher Harvin joins us as Chief International Advisor. Chris has worked in more than 90 countries during his political and communications counsel career. Highlights include having served as Senior Advisor for the Office of Public and Intergovernmental Affairs, as part of the US Department of Veterans Affairs, and being a Founding Partner at Sanitas International - a global strategic communication, public affairs, digital media and political advisory firm. 

Ambassador Pete Hoekstra joins us as Chief Government Affairs Advisor. Pete is Dutch-American, and recently served as the United States Ambassador to The Netherlands. Prior to that he served on the House Intelligence Committee, as Chair and subsequently Ranking Member. Pete was also a Member of the US House of Representatives for Michigan’s 2nd congressional district for an impressive eighteen+ years. 


Lastly, we're happy to announce Dr. Svitlana Kost joins as Quality Control Manager in the Odesa office. Dr. Kost is joining us at an auspicious time as we are entering important rounds of trials this year, and she has already started work on a structural approach for upcoming trials. 


By engaging with these talented individuals, we are investing in the future of orthopaedic medicine. However we can't do it without you - join us as we proceed into what is set to be an exciting and successful year!


*The Chief Medical Officer does not fall under the definitions of Directors or Officers 

Notice of Funds Disbursement

6 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, A.D.A.M. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in A.D.A.M. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Guess the bone implant; new 3D printed samples from A.D.A.M.

6 months ago

Can you guess which parts of the human skeleton these 3D printed implants are for? 

 

On the left are a series of mandible implants for the jaw, and on the right is a cranium implant!

These have been printed using FDM technology with biopolymer & ceramic bio-glass materials. When produced for patients in the future, each implant will be printed to the exact spatial measurements of the individual. As a reminder, these implants are able to be produced at a significantly more affordable rate than traditional titanium implants. They also don't require additional surgeries in the future to be replaced. 

We invite you to join our investor team to be a part of this work, and fuel the future of healthcare. 


Panels, trade shows, and more; a 'day in the life' of A.D.A.M.'s CEO

7 months ago

It's been a busy week for A.D.A.M., with CEO Denys Gurak traveling to partake in several industry events and meetings. 

As previously shared, Denys was invited to be a guest panellist at the forum on Breakthrough Medical Applications of Additive Manufacturing, hosted by the Additive Manufacturing Coalition. The forum prompted some compelling discussion, including around the consideration and benefits of Additive Manufacturing in healthcare in a post-pandemic world. 

This week was also the Advanced Manufacturing East trade show in NYC, one of the largest design and manufacturing events in the US. Pictured below, Denys arriving at the event, and one of the particularly engaging panels; Understanding the Venture Capital Process - Funding Your Next Device. The insights shared by the esteemed panel were particularly relevant to the team. 

Next on the schedule; heading back up to DC for more meetings between A.D.A.M. and the US Department of Defence regarding 3D printing health solutions for wounded soldiers, and how A.D.A.M.'s technology can play a part in this important area of healthcare. 

Round it out with zoom meetings with the R&D lab in Ukraine and testing partners in Israel, Australia and Italy, and it's all in a week's work for the A.D.A.M. staff. We invite you to join A.D.A.M.'s investment team to help continue this forward momentum. To hear more of what we are doing and see behind-the-scenes of the lab, follow us on twitter, LinkedIn, or Facebook.





Notice of Funds Disbursement

7 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, A.D.A.M. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in A.D.A.M. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Happy International 3D Printing Day!

7 months ago

Happy International 3D Printing Day! Held on 3 December (3D..), this year marks 30 years since the invention of the first 3D printer. It’s amazing to consider the progress that has been made in that time, leading to current day innovations such as;

  • A 3D printer orbiting the Earth on the International Space Station, acting as an on-demand manufacturing workspace

  • Printed ‘meat’, including Waygu beef

  • Designs ranging from large scale entirely printed houses, to tiny elements for robots

  • Biodegradable bone implants

Speaking of bone implants...! To mark the day we're happy to share some behind the scenes snaps from the Research & Development lab; whilst these structures may look like building blocks at the beach, they are actually printed test samples. The scaffold structures are part of development research analyzing different internal structures. Pictured during the process; R&D Project Manager Michael Pluzhnik. 

These prints are just a few from a number of samples currently being tested. A.D.A.M. are working with a number of globally recognized universities and medical establishments on several exciting and promising projects. To find out more about these partnerships become an investor today, and be part of the future of healthcare. 




 

A.D.A.M. CEO to be guest panelist in additive manufacturing forum for US Government

7 months ago

CEO Denys Gurak has been invited to speak at a high profile forum organised by the Additive Manufacturing Coalition. 

A.D.A.M. has been in ongoing discussions with the US Department of Defence and Veterans Administration, as they are looking to implement 3D printing in healthcare as one of the primary technologies for treatment of wounded soldiers. As a result of this professional relationship, Mr. Gurak has been invited to speak on a panel by the Additive Manufacturing Coalition. The Coalition is an NGO working to educate the US government on the benefits AM brings to the economy overall, with healthcare bookmarked as one of the primary sectors potentially benefiting from AM.

The upcoming healthcare event is a live online forum Breakthrough Medical Applications of Additive Manufacturing, scheduled for Tuesday December 7th at 3pm EDT. Attendance is open to all interested people and registration is free. If you'd like to listen in to what will be a very interesting panel, RSVP here; https://www.addmfgcoalition.org/events

Mr. Gurak will be joined on the panel by Dr. Matthew Di Prima (Materials Scientist, Food and Drug Administration), Ms. Alyssa Glennon (Principal Engineer, Materialise), and Mr. Gaurav Manchanda (Director of Medical Market Development, Formlabs). 


As A.D.A.M. continues to gain industry and public recognition, now is the time to join our team of investors. 

Competition Finalist and a Podcast: recent highlights for A.D.A.M.

7 months ago

Last month we were thrilled to be a finalist in the Cool Part Showcase; a competition for 3D printed items in the additive manufacturing industry. We were one of four finalists in the Best Proof-of-Concept category with the entry of our Humerus Bone Head - a printed bone implant for the upper arm. 

Being a finalist, the part was on display at the Additive Manufacturing Conference + Expo, where people could see and feel the implant in person. Whilst we didn't take home the win (decided by public vote), it was an honor to be included, and many valuable conversations were sparked.  

Another benefit from being a finalist? We were discussed on the Additive Manufacturing Radio podcast! The episode discusses themes from the Conference, including supply chains, diversity, and disruption (that's us!). An interesting listen for anyone keen to learn about the immediate future of the AM industry. (We're brought up at 20:30 if you'd like to skip ahead). Available on all podcast platforms and link here.

With the industry recognizing us as disruptors to take note of, now is the time to join us as an investor.

 

TV Feature: A.D.A.M. the subject of a dedicated special news report!

7 months ago

It was an exciting day in the R&D lab a couple of weeks ago when the production crew from 1+1 (one of Ukraine's largest TV networks) came to film a special news report about A.D.A.M. The 1+1 network approached us to share our journey to date as a biotech success story, and the special feature recently aired nationally across Ukraine. 

Featuring a behind-the-scenes look at what happens in the lab, CEO Denys Gurak, R&D Project Manager Michael Pluzhnik, and Head of R&D Arkadii Bohdan, MD share their insights. You can even see the 3D printers in action!

This was an independent editorial piece, and not sponsored in any way. To become part of A.D.A.M.'s continuing success story, join our team of investors now. 


A.D.A.M. named by The Economist in '22 Emerging Technologies To Watch in 2022'

7 months ago

We are delighted to share that The Economist has included A.D.A.M. in their feature 'What next? 22 emerging technologies to watch in 2022' - https://www.economist.com/the-world-ahead/2021/11/08/what-next-22-emerging-technologies-to-watch-in-2022

3D-printed bone implants

For years, researchers have been developing techniques to create artificial organs using 3d printing of biological materials. The ultimate goal is to take a few cells from a patient and create fully functional organs for transplantation, thus doing away with long waiting-lists, testing for matches and the risk of rejection.

That goal is still some way off for fleshy organs. But bones are less tricky. Two startups, Particle3d and adam, hope to have 3d-printed bones available for human implantation in 2022. Both firms use calcium-based minerals to print their bones, which are made to measure based on patients’ ct scans. Particle3d’s trials in pigs and mice found that bone marrow and blood vessels grew into its implants within eight weeks. adam says its 3d-printed implants stimulate natural bone growth and gradually biodegrade, eventually being replaced by the patient’s bone tissue. If all goes well, researchers say 3d-printed blood vessels and heart valves are next.


We did not know ahead of time we were being included, so it was a fantastic surprise to be featured in such a globally respected publication. 


2022 will certainly be a big year for A.D.A.M. - now is the perfect time to join us on this path. 

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}